| 摘要 |
<p>The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.</p> |
| 申请人 |
ENANTA PHARMACEUTICALS, INC.;WU, FRANK, X., H.;NAKAJIMA, SUANNE;OR, YAT, SUN;LU, ZHI-HUI;SUN, YING;MIAO, ZHENWEI;WANG, ZHE |
发明人 |
WU, FRANK, X., H.;NAKAJIMA, SUANNE;OR, YAT, SUN;LU, ZHI-HUI;SUN, YING;MIAO, ZHENWEI;WANG, ZHE |
